Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTG-001 in Osteoarthritis of the Knee
2025-522755-26-01Phase 2Authorised
- Sponsor
- Latigo Biotherapeutics
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LTG-001 in knee osteoarthritis (OA) (2 arms), sponsored by Latigo Biotherapeutics. Primary endpoint: Change in WOMAC pain subscale score. Planned start Nov 2025; status: authorised.
02
Drugs
LTG-001
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2025-522755-26-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522755-26-01.